LifeMD, Inc. (NASDAQ:LFMD) Receives $11.57 Consensus PT from Brokerages

by · The Cerbat Gem

LifeMD, Inc. (NASDAQ:LFMD – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the seven brokerages that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $11.57.

Several research analysts recently commented on LFMD shares. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price objective on shares of LifeMD in a report on Monday, November 11th. Lake Street Capital initiated coverage on LifeMD in a research report on Tuesday, December 10th. They issued a “buy” rating and a $12.00 price target for the company. Cantor Fitzgerald reissued an “overweight” rating and set a $15.00 price objective on shares of LifeMD in a report on Friday, September 20th. Finally, Mizuho started coverage on LifeMD in a report on Wednesday, December 4th. They set a “neutral” rating and a $7.00 target price for the company.

View Our Latest Analysis on LifeMD

Insiders Place Their Bets

In other LifeMD news, CEO Justin Schreiber sold 25,000 shares of LifeMD stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $6.52, for a total transaction of $163,000.00. Following the completion of the sale, the chief executive officer now directly owns 2,728,715 shares in the company, valued at $17,791,221.80. The trade was a 0.91 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 15.97% of the company’s stock.

Institutional Trading of LifeMD

Several institutional investors and hedge funds have recently made changes to their positions in LFMD. Quest Partners LLC purchased a new position in LifeMD in the second quarter worth $31,000. nVerses Capital LLC bought a new position in shares of LifeMD during the 3rd quarter valued at about $46,000. Intech Investment Management LLC purchased a new position in shares of LifeMD during the 3rd quarter valued at about $54,000. CWM LLC purchased a new stake in LifeMD in the third quarter worth approximately $59,000. Finally, SG Americas Securities LLC purchased a new stake in LifeMD in the third quarter worth approximately $70,000. Hedge funds and other institutional investors own 35.52% of the company’s stock.

LifeMD Price Performance

Shares of NASDAQ:LFMD opened at $5.22 on Friday. The company has a 50-day moving average price of $5.42 and a two-hundred day moving average price of $5.69. LifeMD has a twelve month low of $3.99 and a twelve month high of $12.88. The company has a quick ratio of 0.78, a current ratio of 0.83 and a debt-to-equity ratio of 10.83. The firm has a market capitalization of $226.09 million, a PE ratio of -8.16 and a beta of 1.38.

LifeMD Company Profile

(Get Free Report

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.

See Also